Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520163 | 1.00 | DNM1 (0.51) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL6236298 | 1.00 | DNM1 (0.51) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL1199794 | 1.00 | DNM1 (0.51) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL16289963 | 0.96 | EPHX2 (0.49) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL18632663 | 0.96 | DNM1 (0.50) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL18632664 | 0.95 | CASP2 (0.51) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL15056475 | 0.95 | MEN1 (0.49) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL15057131 | 0.95 | MEN1 (0.49) | DNM1FAAHMEN1LMNAPOLB | |
| SCHEMBL19655438 | 0.93 | EPHX2 (0.59) | MEN1KMT2AEPHX2ALDH1A1SLC6A5 | |
| SCHEMBL22352182 | 0.93 | EPHX2 (0.59) | MEN1KMT2AEPHX2ALDH1A1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132773-A1 | METHODS AND MATERIALS FOR WELLBORE FLUID DIVERSION USING VISCO-ELASTIC SURFACTANTS | SAUDI ARABIAN OIL COMPANY (SA) | 2024-04-25 | — | — | US | disclosed |
| US-20240133279-A1 | VISCOELASTIC SURFACTANTS FOR ACID DIVERSION IN DOWNHOLE OPERATIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2024-04-25 | — | — | US | disclosed |
| US-11959017-B1 | Methods and materials for wellbore fluid diversion using visco-elastic surfactants | SAUDI ARABIAN OIL COMPANY (SA) | 2024-04-16 | — | — | US | disclosed |
| US-20110071100-A1 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | TILTAN PHARMA LTD. (IL) | 2011-03-24 | — | — | US | disclosed |
| EP-2285369-A2 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | Tiltan Pharma Ltd (IL) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009136396-A2 | SULFOBETAINES FOR THERAPY | TILTAN PHARMA LTD. (IL) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071100-A1 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | MSRB3, BHMT2, GPR119 | DNM1 3404/4885FAAH 625/4885MEN1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.